Drug maker Lupin on Monday said its subsidiary has inked a pact to fully acquire Amsterdam-headquartered VISUfarma BV at an enterprise value of 190 million euros.
The company’s wholly-owned subsidiary, Nanomi BV has signed a definitive agreement for the acquisition of VISUfarma BV, a portfolio company of global healthcare specialist investor GHO Capital Partners LLP, the Mumbai-based drug maker said in a statement.
The acquisition of VISUfarma, with its broad portfolio of eye health products and established commercial infrastructure, aligns with the company’s strategy to expand its European business and footprint and to advance the company’s global specialty franchise, it added.
By integrating VISUfarma’s established commercial operations, Lupin will tap into the attractive ophthalmology market, which is experiencing significant global growth driven by an aging global population, the increasing incidence of diabetes-related eye complications, and growing awareness of preventive care​Drug maker Lupin on Monday said its subsidiary has inked a pact to fully acquire Amsterdam-headquartered VISUfarma BV at an enterprise value of 190 million euros.
The company’s wholly-owned subsidiary, Nanomi BV has signed a definitive agreement for the acquisition of VISUfarma BV, a portfolio company of global healthcare specialist investor GHO Capital Partners LLP, the Mumbai-based drug maker said in a statement.
The acquisition of VISUfarma, with its broad portfolio of eye health products and established commercial infrastructure, aligns with the company’s strategy to expand its European business and footprint and to advance the company’s global specialty franchise, it added.
By integrating VISUfarma’s established commercial operations, Lupin will tap into the attractive ophthalmology market, which is experiencing significant global growth driven by an aging global population, the increasing incidence of diabetes-related eye complications, and growing awareness of preventive care ​Latest News [ SOBAN NEWS: International and National ]
